Cart
sales@molnova.com
SM4
CAS No. 365542-77-4
SM4( —— )
Catalog No. M34426 CAS No. 365542-77-4
SM4 is a SOX18 small molecule inhibitor of HemSC vessel formation in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 141 | Get Quote |
|
| 5MG | 217 | Get Quote |
|
| 10MG | 345 | Get Quote |
|
| 25MG | 572 | Get Quote |
|
| 50MG | 879 | Get Quote |
|
| 100MG | 1251 | Get Quote |
|
| 500MG | 2547 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSM4
-
NoteResearch use only, not for human use.
-
Brief DescriptionSM4 is a SOX18 small molecule inhibitor of HemSC vessel formation in vivo.
-
DescriptionSm4 is a SOX18 inhibitor. Sm4 shows SOX18-DNA binding inhibitory activity. Sm4 selectively affects SOX18 transcriptional output in vitro. Sm4 blocks SoxF transcriptional activity in vivo. Sm4 can be used for cancer metastasis and vascular cancers research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number365542-77-4
-
Formula Weight292.33
-
Molecular FormulaC19H16O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (42.76 mM; Ultrasonic (<60°C)
-
SMILESC(CC1=CC2=C(C=C1)C=CC=C2)C3=C(C(O)=O)C(O)=CC=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mathias FRANCOIS. Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases. Patent, WO2018112545A1.
molnova catalog
related products
-
KHK-IN-1
KHK-IN-1 is a reversible and ATP-competitive inhibitor of ketohexokinase (KHK) with IC50 of 12 nM. In the ATP-binding region of KHK, KHK-IN-1 interacts with Asp-27B.
-
Meranzin
Meranzin is an absorbed bioactive compound from the Traditional Chinese Medicine (TCM) Chaihu-Shugan-San (CSS).?
-
Amatuximab
Amatuximab (MORab-009) is a humanized chimeric IgG1/k monoclonal antibody targeting cell surface mesothelin (MSLN) with antitumor activity for the treatment of solid tumors.
